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Abstract 
Introduction: Venous leg ulceration causes significant pain and suffering for patients, additionally it places 
considerable financial and service burden on the National Health Service (NHS). A large proportion of venous leg 
ulceration do not heal within the standard time frames of 16 – 24 weeks, resulting in static wounds which commonly 
have issues with increasing exudate production. Static wounds can have significant negative impact on the patients 
quality of life, the wound bed and periwound skin, increased risk of infection all of which results in delayed wound 
healing and increased health service costs.  As the NHS continues to face times of austerity, services need to find 
solutions to be able to reduce cost and release nursing time whilst maintaining standards of care. Cutimed® Sorbion® 
Sachet S is a treatment option for the management of patients with a venous leg ulceration. The objective of this 
study was to provide an update of the health economic analysis of Cutimed® Sorbion® Sachet S in comparison to 
relevant comparators in the UK with current cost data. 
Methods: Cutimed® Sorbion® Sachet S was compared against Zetuvit Plus, DryMax extra, KerraMax Care and Eclypse 
from a cost effectiveness perspective. Clinical data were derived from literature and expert opinion. Cost input was 
utilized based on publicly available data and literature. The average patient in the model is assumed to be 65 years 
with a diagnosed venous leg ulcer. It is assumed that patients in the different treatment arms have the same 
background mortality, hence the endpoint mortality is not included in the model. The analysis is based on a 
deterministic Markov model derived from Harding et al. with weekly cycles. The following assumptions are made: 
First, all patients start in a static health state with a non-healed but non-progressing venous leg ulcer. It is assumed in 
the model that patients can transition to a deteriorating health state where a wound is improving or the wound could 
progress. Additionally, venous leg ulcers could be healed from a progressed wound (i.e. improved wound), they could 
develop into a severe wound with complications (infections) to be treated in hospitals. The time frame for the analysis 
was fixed for one year and no re-occurence after healing was assumed to happen. 
Results: The cost-effectiveness analysis demonstrates health economic dominance of Cutimed® Sorbion® Sachet S 
being more effective and cost-saving against all analysed comparators. When using literature-based input values the 
incrementally higher healing rates for Cutimed® Sorbion® Sachet S are 11.04 months (versus Zetuvit Plus), 29.04 
months (versus DryMax extra), 1.68 months (versus KerraMax Care) and 11.04 months (versus Eclypse). Cost savings 
per patient were 37.60£ (versus Zetuvit Plus), 171.68£ (versus DryMax extra), 3.13£ (versus KerraMax Care) and 
43.63£ (versus Eclypse). Clinical benefits and cost savings are increasing when real life practice assumptions based on 
expert opinion are included. 
Conclusions: Based on the underlying health economic model, Cutimed® Sorbion® Sachet S is more effective and less 
costly than other comparative products in venous leg ulcers in the UK. 
3 
 
 
Essity Internal 
Introduction 
Patients with lower limb ulceration are common in clinical practice; within a 1 year period in the United Kingdom 
there were 730,000 leg ulcerations documented, equating to 1.5% of the adult population [1]. The most common 
cause of lower limb ulceration is attributed to venous hypertension with venous ulceration being reported to affect up 
to 1% of all adults increasing to 1.7% for those aged over 65 years [2,3]. Furthermore, the prevalence of leg ulceration 
is known to increase with age [4], with peak prevalence for the development of leg ulceration in patients aged 
between 60 – 80 years [5], therefore, due to an aging population the number of patients affected by venous 
ulceration is likely to rise.  Venous ulceration often takes weeks or months to heal and frequently recur, during the 
time of ulceration high volumes of exudate may be produced, it is painful and even malodorous and all of these issues 
can negatively affect patient’s quality of life [6,7].  The National Health Service (NHS) spends a substantial amount of 
money in the treatment of venous ulceration, mostly through community services, the annual spend on leg ulceration 
was estimated to be around £1.94 billion [8].  
It is acknowledged that the most important treatment for venous ulceration is compression therapy which is designed 
to improve venous return, reduces venous hypertension and hence manages the underlying cause. However, it is also 
vital to ensure that venous leg ulcers are maintained in an ideal environment, which promotes wound healing, one of 
the most vital aspects is the adequate management of wound exudate.  If exudate is not adequately controlled this 
can negatively affect the wound bed and periwound skin, increasing the risk of infection resulting in delayed wound 
healing [9].  The use of advanced wound treatments such as Cutimed® Sorbion® Sachet S could aid the management 
of venous ulceration by providing an ideal wound environment and ensuring effective exudate management, allowing 
for fewer dressing changes, resulting in less nursing visits and therefore providing overall cost savings. 
Consideration of unit cost and comparing this with patient/service benefits is vital when trying to establish overall cost 
effectiveness.  Disease and health economic models can be adopted to demonstrate costs and patient benefits. Health 
economic modelling is a globally recognized technique based on well-documented, international standards [10, 11]. 
Models are developed in order to demonstrate consequences of measurable effects which would only become clear in 
the future. By using health economic evaluation, the effects of cost reimbursement for new medical treatment 
methods may be quantified in relation to existing care modalities [12]. 
Cutimed® Sorbion® Sachet S has been evaluated as a treatment option to control exudate with the ability to progress 
patients from chronic or non-progressing wounds onto improving or healing wounds.  In Panca et al. 2013 an initial 
assessment of various wound dressings in the UK was published. As the clinical basis as well as the cost basis might 
have changed since then. Hence, the objective of this study was to provide an update of the previously published 
health economic analysis of Cutimed® Sorbion® Sachet S [17] in comparison to relevant comparators in the UK with 
current cost data. Analysis of Cutimed® Sorbion® Sachet S was undertaken comparing to Zetuvit Plus, DryMax extra, 
KerraMax Care and Eclypse from a cost effectiveness perspective.   
The question under investigation was: “Is Cutimed® Sorbion® Sachet S cost-effective when compared to alternative 
treatments used to manage venous leg ulcers in the UK?  
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Methods 
To ensure a robust data base for the health economic model, a systematic literature search was conducted in the 
(standard) literature databases Medline through PubMed, INAHTA (International Network of Agencies for Healtth 
Technology Assessment), NHS Economic Evaluation Database and DIMDI (Deutsche Institut für Medizinische 
Dokumentation und Information; German institute for medical documentation and information) for Cochrane Central 
Register of Controlled Trials, Cochrane Database of Systematic Reviews and DAHTA database (German HTA database). 
The research question was defined on the basis of the PICO criteria [13] literature search parmaters were based on 
the PICO. PICO criteria were as follows: 
 Patient & Intervention: chronic wounds, venous leg ulcer, wound care, therapy, diagnostics 
 Comparison: Patients with or without medical therapy or therapy in support of medical devices including 
dressing and bandages 
 Outcomes: Cost, cost-effectiveness, cost per QALY, cost minimization, cost comparison, cost of illness, health 
economics, health economic model, statistical model 
The search was conducted over 12 years (2005 to 2017) in order to focus on the most relevant therapies (and models). 
Included languages were German and English. Inclusion criteria were health economic models and/or health economic 
analysis in the UK ideally with a special focus and clear guidance for a health economic model. Overall there were 831 
hits across all included databases. After title selection and abstract review, full text evaluation was executed for 26 
articles. Overall there were six articles identified in which a UK analysis was provided in venous leg ulcers [14-19]. Of 
these six articles, one was a multinational analysis [16] and four were analyses on specific products without a 
recommendation on health economic modelling approaches.  
Harding et al. [19] was the only article where a general approach in terms of a new costing method was recommended 
which can be utilized as a health economic modelling frame in chronic wounds, and was deemed to be appropriate for 
the underlying research question on which a Markov model was developed. Based on this deterministic Markov model 
with weekly cycles, a cost-effectiveness analysis was performed from the UK NHS payer’s perspective. The time frame 
for the analysis was fixed for one year. The average patient in the model is assumed to be 65 years with a diagnosed 
venous leg ulcer. It is assumed that patients in the different treatment arms have the same background mortality and 
hence it is not included in the model.  
The health states in the model are defined as follows (see Figure 1): 
• "Heal" – Skin is intact (HS 1) 
• "Progress" – Ulcer is progressing towards healing (HS 2) 
• "Static" – Ulcer is neither healing nor deteriorating (HS 3) 
• "Deteriorating" – Ulcer is deteriorating (e.g. increasing in size, exudate or odour; surrounding skin is 
deteriorating) (HS 4) 
• "Severe" – Ulcer is infected or with other complications which may require hospital admission and/or surgical 
intervention“ (HS 5)  
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It is assumed that all patients start in the static health state (HS) with a non-healed and non-progressing venous leg 
ulcer (HS 3). Thereafter, patients can transition to a deteriorating health state (HS 2) where a wound is improving or 
the wound could progress (HS 4). From health state 2 venous leg ulcers could be healed (HS 1) from a progressed 
wound they could develop into a severe wound with complications (infections) to be treated in hospitals (HS 5).  
In other words: All patients in the model start with a currently non healed wound which is not improved (HS 3). At this 
stage in the model, the treating clinician is choosing one of the dressings included in the model. Based on the 
probabilities for these dressings the patient’s wound could improve (health state 2) or could worsen (health state 4). 
Such changes in the wound are being calculated on a weekly basis. Based on the improved wound (health state 2) the 
patient could be healed (health state 1). From a worsened wound (health state 4) the wound could improve (health 
state 3) or even develop complications which would need to be treated in hospitals (health state 5). 
 
Figure 1: Health states within the model based on the patient’s pathway based on Harding et al. [19] 
 
Transition probabilities for the different health states and treatment options available in the model were derived from 
different sources (see Table 1). No re-occurence of wounds after healing happen in this model (HS 1 to HS 3), however 
there is the flexibility analysing such an option in sensitivity analyses. Transition probabilities for moving patients from 
unhealed grade 1 progression (HS 2) to healed were based on Panca et al. [17]. For Zetuvit Plus and Eclypse, neither 
are included in the Panca et al. 2013 analysis, the average transition probability was assumed between Drymax extra, 
KerraMax Care and that Cutimed® Sorbion® Sachet S  as follows: Cutimed® Sorbion® Sachet S’ efficacy in terms of 
healing was taken from Panca et al. 2013. Transition probabilities for unhealed grade 1 static to unhealed grade 1 
progression (HS 3 to HS 2) and unhealed grade 1 deteriorating (HS 4) to unhealed grade 2 severe (HS 5) were both 
taken from Shannon et al. 2016 [20] and assumed to be independent to the underlying treatment. The transition 
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probability for unhealed grade 1 static to unhealed grade 1 deteriorating (HS 3 to HS 4) was based on Walzer et al. 
2016 [21]. 
Furthermore, it was assumed that all patients received two wound dressing changes per week regardless of the 
underlying treatment. 
Table 1: Transition probabilities for the different treatment in the various health states of the underlying model 
 
 
 
 
Model 
path 
Transition probability (per week) Reference 
Zetuvit 
Plus 
DryMax 
extra 
KerraMax 
Care 
Eclypse Cutimed® 
Sorbion® 
Sachet S 
Healed to unhealed grade 1 
static 
HS 1 to 
HS 3 
0.0000 0.0000 0.0000 0.0000 0.0000 Assumption: No 
recurrence 
Unhealed grade 1 progression 
to healed 
HS 2 to 
HS 1 
0.0180 0.0144 0.0200 0.0180 0.0204 Assumptions 
based on Panca et 
al. 2013 [17] 
Unhealed grade 1 static to 
unhealed grade 1 progression 
HS 3 to 
HS 2 
0.0600 0.0600 0.0600 0.0600 0.0600 Shannon et al. 
2016 [20] 
Unhealed grade 1 static to 
unhealed grade 1 
deteriorating 
HS 3 to 
HS 4 
0.0188 0.0188 0.0188 0.0188 0.0188 Walzer et al. 2016 
[21] 
Unhealed grade 1 
deteriorating to unhealed 
grade 2 severe 
HS 4 to 
HS 5 
0.0040 0.0040 0.0040 0.0040 0.0040 Shannon et al. 
2016 [20] 
Unhealed grade 2 severe to 
unhealed grade 1 static 
HS 5 to 
HS 3 
0.8000 0.8000 0.8000 0.8000 0.8000 Walzer et al. 2016 
[21] 
 
The health state utilities were determined through investigation of EQ-5D data from a one-year pragmatic, 
randomized longitudinal venous leg ulcer study (VenUS III) completed in the United Kingdom [22]. An EQ-5D five-
dimension score (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) recorded within 0 to 3 
weeks of each documented health state was identified in the VenUS III dataset and then translated into a EQ-5D index 
score (utility value). Translation of five-dimension score to the index score was completed using an EQ-5D index 
calculator. The utilities for the health states “progressing“ and “deteriorating“ were assumed to be the same (see 
Table 2).  
Table 2: Utilities of individual health states in the model based on Shannon et al. 2016 [22] 
Health State Utility 
Healed (HS 1) 0.630 
Progressing (HS 2) 0.534 
Static (HS 3) 0.525 
Deteriorating (HS 4)  0.534 
Severe (HS 5) 0.130 
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The costs for the various health states were directly taken from Harding et al. [18] (see Table 3). Once a patient is 
healed quarterly outpatient visits are assumed (based on expert opinion), costs derived from experts at the 
University of Huddersfield.  
Table 3: Cost input for the health economic model 
Cost items Cost per week Reference 
Healed (HS 1) £ 6.04 Harding et al. 2013 [19] 
Progressing (HS 2) £ 87.59 Harding et al. 2013 [19] 
Static (HS 3) £ 100.27 Harding et al. 2013 [19] 
Deteriorating (HS 4)  £ 159.45 Harding et al. 2013 [19] 
Severe (HS 5) £ 637.15 Harding et al. 2013 [19] 
Cost per outpatient visit 
(“administration cost”) 
£ 2.48 Expert opinion 
 
The individual costs of each therapy have been taken into account per dressing (see Table 4). It was assumed, that 
each time a wound dressing was changed, a new dressing was applied (from the same manufacturer).  The costs of 
additional wound care products have not been included in the calculations, assuming that similar products and 
consequently similar cost would arise.  
Table 4: Package price input per therapy and week (package assumption for pack size: 10x10) 
Product Cost per package (use per wound 
dressing) 
Reference 
Zetuvit Plus £ 0.64 Public UK price (April 2017) [23] 
DryMax extra £ 0.87 Public UK price (April 2017) [23] 
KerraMax Care £ 1.29 Public UK price (April 2017) [23] 
Eclypse £ 0.73 Public UK price (April 2017) [23] 
Cutimed® Sorbion® Sachet S £ 1.49 Public UK price (April 2017) [23] 
 
Healing of the wound is the primary efficacy endpoint and is also the basis for the cost per QALY analysis in the model. 
Both the total costs and the respective cost of care per health state were determined as cost endpoints. Finally, the 
efficacy and cost endpoints of the model are compared to calculate the incremental cost-effectiveness ratio (ICER). 
The calculation is performed as the difference of the total costs between a Cutimed® Sorbion® Sachet S therapy and 
the respective treatment options Zetuvit Plus, DryMax extra, KerraMax Care and Eclypse, respectively. Analogically, 
the incremental efficacy was calculated based on the respective efficacy values. Finally, the incremental cost-
effectiveness has been calculated and both, the costs per additional year of healing and the costs per QALY (quality 
adjusted life year) gained, are determined [12].  
The ICER was calculated as follows: 
            (Cutimed® Sorbion® Sachet S costs) – (comparative therapy costs)        
ICER =                                                                                                                                                                                                                                                                                                                                                                                           . 
(Cutimed® Sorbion® Sachet S efficacy) – (comparative therapy efficacy) 
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Sensitivity analyses were executed on key variables of the model. Expert opinion (VLU clinician in cooperation with a 
wound nurse) on the transition probabilities for each health state were utilized in order to implement a “real life” 
input into the model (see Table 5). Within that process experts were asked how many patients out of 100 patients 
would get one of the health states below. Health states were described for clinical personell in order to get adequate 
responses, 
Table 5: Changed transition probabilities for the different treatments in the various health states of the underlying 
model in sensitivity analysis 
 
 
 
 
Model 
path 
Transition probability (per week) Reference 
Zetuvit 
Plus 
DryMax 
extra 
KerraMax 
Care 
Eclypse Cutimed® 
Sorbion® 
Sachet S 
Unhealed grade 1 static to 
unhealed grade 1 progression 
HS 3 to 
HS 2 
0.5000 0.5000 0.5000 0.5000 0.5000 Expert opinion 
Unhealed grade 1 static to 
unhealed grade 1 
deteriorating 
HS 3 to 
HS 4 
0.3000 0.3000 0.3000 0.3000 0.3000 Expert opinion 
Unhealed grade 1 
deteriorating to unhealed 
grade 2 severe 
HS 4 to 
HS 5 
0.1000 0.1000 0.1000 0.1000 0.1000 Expert opinion 
Unhealed grade 2 severe to 
unhealed grade 1 static 
HS 5 to 
HS 3 
0.1000 0.1000 0.1000 0.1000 0.1000 Expert opinion 
 
Results 
The total costs per patient per year are reported in Table 6. According to the model, for a patient with Cutimed® 
Sorbion® Sachet S the costs amount to £ 61.99. The main cost drivers are the costs in the progression (HS 2) and 
deteriorating (HS 4) health states, which account for more than 71% of the total costs (£ 4,699.38). In contrast to this, 
the total annual costs with Zetuvit Plus, DryMax extra and Eclypse are £ 4,736.98, £ 4,871.07, £ 4,702.51 and £ 
4,743.01 respectively.  
Table 6: Cost comparison results in the treatment of venous leg ulcers in the UK 
Health state Zetuvit DryMax extra KerraMax Care Eclypse Cutimed® 
Sorbion® Sachet S 
Healed (HS 1) £ 56.49 £ 47.44 £ 61.22 £ 56.49 £62.07  
Progression (HS 2) £ 1,909.62 £ 2,040.90 £ 1,841.09 £ 1,909.62 £ 1,828.79 
Static (HS 3) £ 1,261.67 £ 1,267.36 £ 1,277.31 £ 1,264.04 £ 1,282.05 
Deteriorating (HS 4) £ 1,481.50 £ 1,487.66 £ 1,495.18 £ 1,485.15 £ 1,498.76 
Severe (HS 5) £ 27.71 £ 27.71 £ 27.71 £ 27.71 £ 27.71 
Total cost £ 4,736.98 £ 4,871.07 £ 4,702.51 £ 4,743.01 £ 4,699.38 
 
The higher healing rates in the effect assumption (see Table 1 vs Table 5) for Cutimed® Sorbion® Sachet S can also be 
affirmed in the higher incremental effect in the total calculation (see Table 7). Given the higher utility values for the 
healed health state this advantage is also transferred into the incremental QALYs. The incremental cost-effectiveness, 
as reported in Table 7, is calculated from the modelled efficacy, calculated for an additionally healed patient, and the 
total costs accordingly. The difference in the incremental costs shows the difference in the total costs for the 
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treatments to be compared. Finally, the incremental cost-effectiveness puts the difference in the costs in relation to 
the difference in the healings. According to the model, a Cutimed® Sorbion® Sachet S therapy is more effective and 
cost-saving and can therefore be regarded as dominant in relation to the other four analysed therapies from a health 
economic’s viewpoint.  
Table 7: Cost-effectiveness results from a UK payer's perspective 
Comparison Incremental effect 
(“healed”) 
Incremental 
cost 
Incremental 
utilities (“QALY”) 
Incremental cost-
effectiveness 
Incremental cost 
per QALY 
Cutimed® Sorbion® 
Sachet S versus 
Zetuvit Plus 
0.92 years 
(11.04 months) 
£ 37.60 0.0017 - £ 40.75 - £ 22,073.30 
Cutimed® Sorbion® 
Sachet S versus 
DryMax extra 
2.42 years 
(29.04 months) 
£ 171.68 0.0045 - £ 70.90 - £ 38,403.23 
Cutimed® Sorbion® 
Sachet S versus 
KerraMax Care 
0.14 years 
(1.68 months) 
£ 3.13 0.0003 - £ 22.28 - £ 12,065.77 
Cutimed® Sorbion® 
Sachet S versus 
Eclypse 
0.92 years 
(11.04 months) 
£ 43.63 0.0017 - £ 47.28 - £ 25,612.37 
 
The results of the base case analysis are also confirmed in the sensitivity analysis (see Table 8). Sorbion® Sachet S 
remains to be dominant from a health economic perspective. It is more effective and less costly against the four 
different other wound care therapies.  
Table 8: Sensitivity analysis results on the cost-effectiveness a UK payer's perspective 
Comparison Incremental effect 
(“healed”) 
Incremental 
cost 
Incremental 
utilities (“QALY”) 
Incremental cost-
effectiveness 
Incremental cost 
per QALY 
Cutimed® Sorbion® 
Sachet S versus 
Zetuvit 
1.27 years 
(15.24 months) 
£ 3792.71 0.0023 - £ 73.02 - £ 39,552.51 
Cutimed® Sorbion® 
Sachet S versus 
DryMax extra 
3.35 years 
(40.2 months) 
£ 265.38 0.0062 - £ 79.26 - £ 42,932.70 
Cutimed® Sorbion® 
Sachet S versus 
KerraMax Care 
0.19 years 
(2.28 months) 
£ 13.24 0.0004 - £ 68.71 - £ 37,219.82 
Cutimed® Sorbion® 
Sachet S versus 
Eclypse 
1.27 years 
(15.24) 
£ 94.14 0.0023 - £ 74.15 - £ 40,163.92 
 
Discussion 
The present analysis is an updated cost-effectiveness analysis related to Cutimed® Sorbion® Sachet S in the UK [17]. 
The initial procurement costs of Cutimed® Sorbion® Sachet S are negated when compared to the improved wound 
healing rates leading to reduced dressing changes, time for nurse visits and improved outcomes.  However, as there 
are no randomized controlled trials available comparing different wound therapies against each other based on 
patient relevant endpoints such as healing, assumptions had to be taken between the therapies. The transition 
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probabilities were assumed to be the same between the therapies for all health states except HS 2 transitioning to HS 
1. These assumptions were taken from a published analysis by Panca et al. [17] and re-calculated into weekly 
probabilities. When changing the transition probabilities for the different health states from literature-based into real 
life expert opinions the results were quantitively different, however the direction of the results remains the same. 
Cutimed® Sorbion® Sachet S remains more effective and less costly.  
Limitations  
Markov models have been critised as they might simplify reality further in comparison to other modelling approaches 
[12]. A key issue may be the exclusion of the majority of items included in the analysis, such as patient characteristics. 
In Markov models, cohorts are modelled instead of individual patients with specific characteristics and its correlation 
and covariates to clinical outcome parameters. Nevertheless, the underlying model is a well defined clinical snapshot 
of the reality including detailed health states during the different steps of a patient’s journey.  
Additionally, the clinical input values for the five therapies included in the analysis are based on assumptions and 
clinical data without direct evidence between those; similar to already published health economic evidence [17]. 
Based on the limited data availability also a network meta-analysis to derive the adjusted indirect evidence was not 
feasible. 
Cost data are based on Harding et al. [19]. However, their analysis mainly focused on testing a cost methodology even 
though the utilized data was derived directly from different treatment centers across the UK. In the analysis, it was 
shown that the key modelling parameter was the probability of healing, although healing was not proven in any of the 
underlying therapies. However, in Panca et al. [17] similar assumptions were utilized and also aligned with clinical 
experts in the UK who experienced similar numbers in real life settings. 
 
Conclusion 
The management of patients with venous leg ulceration is a daily challenge to many UK clinicians, the key to effective 
management is compression therapy, yet there are occasions when venous ulcerations fail to show signs of healing 
and issues with high volumes of exudate are common place.  Cutimed® Sorbion® Sachet S provides an ideal wound 
environment to allow healing to occur with the added advantage of being able to handle high volumes of exudate 
ensuring that the wound is protected from the damaging effects of uncontrolled moisture.  Based on this health 
economic modelling, Cutimed® Sorbion® Sachet S has been shown to be more effective in promoting healing and less 
costly when compared to other comparative dressings within the UK.  
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